-
Meta-analysis of the clinical performance of commercial SARS-CoV-2 nucleic acid and antibody tests up to 22 August 2020
-
View Affiliations Hide AffiliationsIvo Van Walleivo.van.walle rivm.nl
-
View Collaborators
European COVID-19 microbiological laboratories group: Marjan Van Esbroeck, Kurt Beuselinck, Pieter Vermeersch, Christos Karagiannis, Andreas Mentis, Stavroula Lampropoulou, Iris Erlund, Merit Melin, Nina Ekström, Terhi Vihervaara, Alexandre Gaymard, Emilie Frobert, Vanessa Escuret, Ivan-Christian Kurolt, Guillaume Fournier, Tamir Abdelrahman, Trung Nguyen, Adrian Klak, Anne E Bos, Anne Russcher, Annemarie van ’t Veen, Annette M Stemerding, Annette van Corteveen-Splinter, Babette C van Hees, Bas B Wintermans, Bjorn L Herpers, Chantal BEM Reusken, Christel FM van der Donk, Claudy Oliveira dos Santos, Corine H GeurtsvanKessel, Cornelis P Timmerman, David SY Ong, Deborah J Kaersenhout, Ellen van Lochem, Felix Geeraedts, Ger T Rijkers, Hannke Berkhout, Hans GM Koeleman, Inge HM van Loo, Janette Rahamat-Langendoen, Jean-Luc Murk, Jeroen HT Tjhie, Johan Kissing, Johan Reimerink, Jos J Kerremans, Jutte JC de Vries, Karen A Heemstra, Khoa TD Thai, Kin Ki Jim, Leontine Mulder, Maaike JC van den Beld, Manou R Batstra, Maria M Konstantinovski, Marjolijn CA Wegdam-Blans, Martine Hoogewerf, Melanie J de Graaf, Menno D. de Jong, Michiel Heron, Michiel van Rijn, Moniek Heusinkveld, Nathalie Van Burgel, Paul HM Savelkoul, Paul Martijn den Reijer, Peter C Wever, Peter Croughs, Rens Zonneveld, Sim van Gyseghem, Steven FT Thijsen, Susanne P Stoof, Suzanne Jurriaans, Sylvia B Debast, Theo Mank, Vishal Hira, Aleksander Michalski, Anna Siewierska-Puchlerska, Ewa Gajda, Jarosław Paciorek, Marta Pakieła, Agnieszka Kołakowska-Kulesza, Katarzyna Pancer, Magdalena Nowakowska, Inês Costa, Líbia Zé-Zé, Raquel Guiomar, Berit Hammas, Johan Brynedal Öckinger, Katarina Prosenc, Nataša BergincView Citation Hide Citation
Citation style for this article: . Meta-analysis of the clinical performance of commercial SARS-CoV-2 nucleic acid and antibody tests up to 22 August 2020. Euro Surveill. 2021;26(45):pii=2001675. https://doi.org/10.2807/1560-7917.ES.2021.26.45.2001675 Received: 12 Sept 2020; Accepted: 16 Aug 2021
Abstract
Reliable testing for SARS-CoV-2 is key for the management of the COVID-19 pandemic.
We estimate diagnostic accuracy for nucleic acid and antibody tests 5 months into the COVID-19 pandemic, and compare with manufacturer-reported accuracy.
We reviewed the clinical performance of SARS-CoV-2 nucleic acid and antibody tests based on 93,757 test results from 151 published studies and 20,205 new test results from 12 countries in the European Union and European Economic Area (EU/EEA).
Pooling the results and considering only results with 95% confidence interval width ≤ 5%, we found four nucleic acid tests, including one point-of-care test and three antibody tests, with a clinical sensitivity ≥ 95% for at least one target population (hospitalised, mild or asymptomatic, or unknown). Nine nucleic acid tests and 25 antibody tests, 12 of them point-of-care tests, had a clinical specificity of ≥ 98%. Three antibody tests achieved both thresholds. Evidence for nucleic acid point-of-care tests remains scarce at present, and sensitivity varied substantially. Study heterogeneity was low for eight of 14 sensitivity and 68 of 84 specificity results with confidence interval width ≤ 5%, and lower for nucleic acid tests than antibody tests. Manufacturer-reported clinical performance was significantly higher than independently assessed in 11 of 32 and four of 34 cases, respectively, for sensitivity and specificity, indicating a need for improvement in this area.
Continuous monitoring of clinical performance within more clearly defined target populations is needed.
Full text loading...